Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00995787 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00995787 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 75 participants.
The verdict
NCT00995787, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.
Interventions
- DRUG Placebo
- DRUG AZD1656
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00995787
The ClinicalTrials.gov registry entry for NCT00995787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00995787 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00995787 about?
NCT00995787 is a clinical study titled "Safety and Tolerability of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients Treated With Metformin and Sulfonylurea". The primary aim of this study is to evaluate the safety and tolerability of AZD1656 in T2DM patients treated with metformin and sulfonylurea.
What is the current status of trial NCT00995787?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2009-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00995787?
The interventions under investigation include: Placebo (DRUG), AZD1656 (DRUG).
Who is sponsoring clinical trial NCT00995787?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.